Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pediatric Endocrinology

Long-term Monitoring and Family Screening

At a Glance

Long-term FH4 care combines regular potassium, renin, creatinine, and eGFR checks with medication and sodium management to protect the heart and kidneys. Because it can pass from parent to child, first-degree relatives may need genetic counseling and testing.

Managing Familial Hyperaldosteronism Type IV (FH4) is a marathon, not a sprint. Because this condition is caused by a lifelong genetic variant, care focuses on long-term protection of the heart and kidneys [1]. Success is not just about the numbers on a blood pressure monitor today; it is about consistent monitoring, adjusting to the physical changes of growing up, and ensuring that other family members have the information they need to stay healthy.

Essential Long-Term Monitoring

Once your child is on a stable dose of medication, usually a mineralocorticoid receptor antagonist (MRA), regular check-ups are necessary to ensure the treatment remains safe and effective.

  • Potassium and Renin Tracking: The goal is to keep potassium in a normal range without needing supplements. Specialists also track renin; a rise in renin levels (un-suppression) is one marker that the medication is successfully blocking the extra aldosterone, though it must be interpreted with other lab results [2][3][4].
  • Kidney Function (eGFR): It is common for kidney function (measured by creatinine and eGFR) to appear to “drop” slightly when you first start treatment [5]. This can show that the medication is correcting the “over-filtering” caused by high blood pressure. However, any meaningful change must be reviewed by your clinician. It could also signal volume depletion, excessive dosing, or acute kidney injury [6]. Pediatric eGFR is heavily dependent on age and height.
  • Routine Frequency: While there is no universal schedule, doctors must check labs (especially potassium and creatinine) shortly after starting or changing a dose, and then move to a less frequent schedule once the condition is stable [7].

Managing Medication and Side Effects

The two primary medications used, spironolactone and eplerenone, work well but have different profiles. Never start, stop, or change these medications without medical advice.

Spironolactone

This is often the first choice because it is effective and widely available. However, it can affect other hormones in the body.

  • Side Effects: In boys, it can cause gynecomastia (breast enlargement or tenderness). In girls, it can lead to irregular menstrual cycles [8][9].
  • Dose Sensitivity: Because pediatric dosing is weight-based, families should report breast tenderness, menstrual changes, or other puberty-related concerns to their doctor at any dose [10].

Eplerenone

If side effects become an issue, doctors often switch to eplerenone. It is more “selective,” meaning it specifically targets the aldosterone receptor and is much less likely to cause hormonal side effects [8]. It may need to be taken twice a day to be fully effective [11].

The Power of Cascade Screening

FH4 is an autosomal dominant condition [1].

Cascade screening is the process of testing all first-degree relatives once a pathogenic or likely pathogenic variant is found [12].

  • Inheritance Odds: If a parent has the pathogenic variant, each pregnancy has a 50% chance of inheriting it. A sibling’s risk depends entirely on whether a parent carries the variant, as it can sometimes occur de novo (new) in the child.
  • Testing Even if “Healthy”: Some people carry the variant but have very mild symptoms that go unnoticed for years [13]. Early protection allows them to start monitoring before the high blood pressure causes silent damage [1].
  • Genetic Counseling: Families are encouraged to meet with a genetic counselor to understand how to share this information and what it means for reproductive planning [14]. Testing relatives for a Variant of Uncertain Significance (VUS) should be avoided.

Daily Management and Sodium

Medication is only one part of the strategy. Dietary sodium (salt) restriction is an important part of helping the treatment work [15].

  • Why it Matters: High salt intake forces the body to hold onto more fluid, making the heart work harder and making it more difficult for MRAs to block aldosterone [16].
  • The Target: Use individualized, age-appropriate dietary guidance to lower sodium without being overly restrictive [17]. Focus on fresh foods and avoid “hidden” sodium in processed items [18].
  • CRITICAL WARNING: Do not use potassium-containing salt substitutes. MRAs already raise potassium levels, and adding a salt substitute can lead to dangerous, life-threatening hyperkalemia.

Common questions in this guide

What blood tests are used to monitor FH4 treatment?
Clinicians commonly follow potassium, creatinine and eGFR, and renin after an MRA is started or its dose changes, then periodically once treatment is stable. The exact schedule depends on the child’s age, dose, kidney function, and results.
Is a lower eGFR after starting an FH4 medicine always kidney damage?
Not always. A small early change can reflect correction of high-blood-pressure-related over-filtering, but a meaningful change may also signal dehydration, too much medication, or acute kidney injury and should be reviewed by the child’s clinician.
What side effects can spironolactone cause in children?
Spironolactone can cause breast enlargement or tenderness in boys and irregular menstrual cycles in girls. Families should report these or other puberty-related changes to the clinician instead of changing the dose themselves.
Why might a child with FH4 switch from spironolactone to eplerenone?
Eplerenone acts more selectively at the aldosterone receptor and is less likely to cause hormonal side effects than spironolactone. It may need to be taken twice a day, and the child’s clinician can decide whether switching is appropriate.
Should relatives be tested when a child has a pathogenic CACNA1H variant?
FH4 is autosomal dominant, so each child of a parent who carries the pathogenic variant has a 50% chance of inheriting it. After a pathogenic or likely pathogenic variant is identified, cascade testing and genetic counseling are generally offered to first-degree relatives; relatives should not be tested for a variant of uncertain significance solely for family screening.
Can a child with FH4 use a potassium-containing salt substitute?
Potassium-containing salt substitutes should not be used unless the child’s clinician specifically recommends them, because MRAs can raise potassium and the combination can cause dangerous hyperkalemia. Families should use individualized, age-appropriate sodium guidance and limit highly processed foods.
What should we do if a child taking an MRA has severe vomiting or diarrhea?
Severe vomiting or diarrhea can cause dehydration and affect kidney function and medication safety. Contact the child’s care team promptly for individualized instructions, and do not start, stop, or change the medicine without medical advice.

Get notified when new evidence is published on Familial hyperaldosteronism type IV.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management of CACNA1H-Related Primary Aldosteronism: A Systematic Review.

    Michalski W, Jaszczyszyn I, Bielska W, Stolarczyk A

    Journal of clinical medicine 2026; (15(10)) doi:10.3390/jcm15103693.

    PMID: 42194655
  2. 2

    Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.

    Adler GK, Stowasser M, Correa RR, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.

    PMID: 40658480
  3. 3

    Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

    Hundemer GL, Leung AA, Kline GA, et al.

    Endocrine reviews 2024; (45(1)):69-94 doi:10.1210/endrev/bnad024.

    PMID: 37439256
  4. 4

    Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis.

    Katsuragawa S, Le MV, Fuller PJ, Yang J

    The lancet. Diabetes & endocrinology 2025; (13(12)):1041-1053 doi:10.1016/S2213-8587(25)00263-3.

    PMID: 41235994
  5. 5

    Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.

    Kobayashi H, Abe M, Nakamura Y, et al.

    Hypertension (Dallas, Tex. : 1979) 2019; (74(3)):630-638 doi:10.1161/HYPERTENSIONAHA.119.13131.

    PMID: 31327258
  6. 6

    Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

    Katsuragawa S, Goto A, Shinoda S, et al.

    Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

    PMID: 37449450
  7. 7

    Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.

    Saiki A, Otsuki M, Tamada D, et al.

    Journal of the Endocrine Society 2022; (6(1)):bvab174 doi:10.1210/jendso/bvab174.

    PMID: 34909517
  8. 8

    Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis.

    Ho WY, Hsiao CC, Wu PH, et al.

    Therapeutic advances in chronic disease 2024; (15()):20406223241239775 doi:10.1177/20406223241239775.

    PMID: 38511069
  9. 9

    Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain.

    Goi J, Paja Fano M, Rizo Gellida A, et al.

    European journal of endocrinology 2025; (193(2)):297-309 doi:10.1093/ejendo/lvaf158.

    PMID: 40743244
  10. 10

    Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism.

    Tang F, Loh LM, Foo RS, et al.

    Journal of the Endocrine Society 2021; (5(11)):bvab144 doi:10.1210/jendso/bvab144.

    PMID: 34541440
  11. 11

    Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.

    Karashima S, Yoneda T, Kometani M, et al.

    Hypertension research : official journal of the Japanese Society of Hypertension 2016; (39(3)):133-7 doi:10.1038/hr.2015.129.

    PMID: 26606875
  12. 12

    Enhanced Ca2+ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1h ).

    Seidel E, Schewe J, Zhang J, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2021; (118(17)) doi:10.1073/pnas.2014876118.

    PMID: 33879608
  13. 13

    [Analysis of a family with familial hyperaldosteronism type Ⅳ due to a mutation in the CACNA1H gene].

    Zhu ZF, Li AZ, Yan ZL, et al.

    Zhonghua yi xue za zhi 2025; (105(35)):3090-3094 doi:10.3760/cma.j.cn112137-20250409-00883.

    PMID: 40953980
  14. 14

    Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

    Mulatero P, Scholl UI, Fardella CE, et al.

    European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.

    PMID: 38571460
  15. 15

    Treatment of Primary Aldosteronism.

    Parisien-La Salle S, Hundemer GL, Nehs MA, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.

    PMID: 41808633
  16. 16

    Outcomes of drug-based and surgical treatments for primary aldosteronism.

    Steichen O, Lorthioir A, Zinzindohoue F, et al.

    Advances in chronic kidney disease 2015; (22(3)):196-203.

    PMID: 25908468
  17. 17

    Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial.

    Zhou L, Jiang Y, Zhang C, et al.

    Frontiers in endocrinology 2023; (14()):1124479 doi:10.3389/fendo.2023.1124479.

    PMID: 37152926
  18. 18

    Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism.

    Adolf C, Schneider H, Heinrich DA, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(6)):386-393 doi:10.1055/a-1116-2407.

    PMID: 32252107

This page explains long-term monitoring, medication safety, sodium guidance, and family screening for FH4 for informational purposes only; it does not constitute medical advice or replace care from your child’s medical and genetics team.